Royalty Pharma (RPRX) Profit After Tax (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Profit After Tax data on file, last reported at $294.7 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 23.12% year-over-year to $294.7 million; the trailing twelve-month figure through Mar 2026 stood at $632.2 million (down 56.07% YoY), and the FY2025 full-year result was $770.9 million, down 10.25% from the prior year.
• Profit After Tax rose to $294.7 million in Q1 2026, from -$197.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $1.1 billion in Q4 2023 to a low of -$268.9 million in Q4 2022.
• A 5-year average of $261.1 million and a median of $208.2 million in 2024 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax sank 3501.47% in 2022 and soared 4909.4% in 2025, its largest moves.
• Tracing RPRX's Profit After Tax over 5 years: stood at -$268.9 million in 2022, then soared by 494.12% to $1.1 billion in 2023, then slumped by 80.35% to $208.2 million in 2024, then tumbled by 194.77% to -$197.3 million in 2025, then soared by 249.34% to $294.7 million in 2026.
• Business Quant data shows RPRX's Profit After Tax at $294.7 million in Q1 2026, -$197.3 million in Q4 2025, and $444.2 million in Q3 2025.